Wellington Management Group LLP Has $326,000 Stake in Alto Neuroscience, Inc. (NYSE:ANRO)

Wellington Management Group LLP raised its holdings in Alto Neuroscience, Inc. (NYSE:ANRO) by 27.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 77,146 shares of the company’s stock after buying an additional 16,510 shares during the period. Wellington Management Group LLP owned 0.29% of Alto Neuroscience worth $326,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANRO. BNP Paribas Financial Markets grew its holdings in shares of Alto Neuroscience by 619.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after acquiring an additional 3,715 shares in the last quarter. Rhumbline Advisers grew its stake in Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after purchasing an additional 5,008 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Alto Neuroscience by 15.0% in the fourth quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company’s stock valued at $221,000 after purchasing an additional 6,812 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Alto Neuroscience during the 3rd quarter worth approximately $124,000. Finally, Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Alto Neuroscience during the 4th quarter worth approximately $74,000.

Alto Neuroscience Trading Down 0.9 %

Shares of Alto Neuroscience stock opened at $2.11 on Tuesday. Alto Neuroscience, Inc. has a 1 year low of $1.60 and a 1 year high of $17.55. The company has a market capitalization of $57.12 million, a price-to-earnings ratio of -0.83 and a beta of 2.16. The business has a fifty day simple moving average of $2.83 and a two-hundred day simple moving average of $4.72. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09. Research analysts forecast that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Analyst Upgrades and Downgrades

ANRO has been the subject of several analyst reports. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. HC Wainwright began coverage on shares of Alto Neuroscience in a research report on Monday, April 7th. They issued a “buy” rating and a $10.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.40.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.